Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) EBIT (2016 - 2026)

Oramed Pharmaceuticals filings provide 14 years of EBIT readings, the most recent being $25.2 million for Q4 2025.

  • Quarterly EBIT rose 331.87% to $25.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.8 million through Dec 2025, up 573.17% year-over-year, with the annual reading at $15.8 million for FY2025, 573.17% up from the prior year.
  • EBIT hit $25.2 million in Q4 2025 for Oramed Pharmaceuticals, up from -$2.4 million in the prior quarter.
  • Across five years, EBIT topped out at $25.2 million in Q4 2025 and bottomed at -$24.2 million in Q3 2021.
  • Average EBIT over 5 years is -$3.2 million, with a median of -$3.1 million recorded in 2024.
  • The largest annual shift saw EBIT crashed 54.92% in 2024 before it skyrocketed 331.87% in 2025.
  • Oramed Pharmaceuticals' EBIT stood at -$24.2 million in 2021, then skyrocketed by 49.11% to -$12.3 million in 2022, then skyrocketed by 205.14% to $13.0 million in 2023, then crashed by 54.92% to $5.8 million in 2024, then skyrocketed by 331.87% to $25.2 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's EBIT are $25.2 million (Q4 2025), -$2.4 million (Q3 2025), and -$2.5 million (Q2 2025).